Answers are grounded in this paper and cite their sources.
Malaria Vaccine. Developed through a collaboration between the University of Oxford and Novavax, this vaccine has demonstrated remarkable efficacy, reaching 77% effectiveness in Phase 2 clinical trials. It is designed to be low-dose, cost-effective, and accessible, with approval for use in children under three years old. This perspective paper critically examines the R21/Matrix-M malaria vaccine, its development, potential impact on global malaria eradication efforts, and the challenges and opportunities it presents.
No takes yet. Share an insight, caveat, or question.
Aderinto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: